Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

SN Lone, S Nisar, T Masoodi, M Singh, A Rizwan… - Molecular cancer, 2022 - Springer
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

P Johnson, Q Zhou, DY Dao, YMD Lo - … reviews Gastroenterology & …, 2022 - nature.com
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer

J Tie, JD Cohen, K Lahouel, SN Lo… - … England Journal of …, 2022 - Mass Medical Soc
Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J Pascual, G Attard, FC Bidard, G Curigliano… - Annals of …, 2022 - Elsevier
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

T Powles, ZJ Assaf, N Davarpanah, R Banchereau… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

P Stejskal, H Goodarzi, J Srovnal, M Hajdúch… - Molecular cancer, 2023 - Springer
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Liquid biopsy enters the clinic—implementation issues and future challenges

M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Circulating tumour DNA—looking beyond the blood

A Tivey, M Church, D Rothwell, C Dive… - Nature reviews clinical …, 2022 - nature.com
Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Clinical trial design in the era of precision medicine

E Fountzilas, AM Tsimberidou, HH Vo, R Kurzrock - Genome medicine, 2022 - Springer
Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …